DexCom (DXCM) versus Cytori Therapeutics (CYTX) Critical Review
DexCom (NASDAQ: DXCM) and Cytori Therapeutics (NASDAQ:CYTX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Valuation and Earnings
This table compares DexCom and Cytori Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|DexCom||$632.70 million||6.19||-$63.30 million||($0.77)||-58.75|
|Cytori Therapeutics||$8.75 million||1.63||-$17.75 million||($1.02)||-0.40|
Cytori Therapeutics has higher revenue, but lower earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Cytori Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares DexCom and Cytori Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
11.8% of Cytori Therapeutics shares are owned by institutional investors. 1.7% of DexCom shares are owned by company insiders. Comparatively, 1.9% of Cytori Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and price targets for DexCom and Cytori Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DexCom presently has a consensus price target of $72.19, suggesting a potential upside of 59.58%. Cytori Therapeutics has a consensus price target of $3.65, suggesting a potential upside of 789.59%. Given Cytori Therapeutics’ higher probable upside, analysts plainly believe Cytori Therapeutics is more favorable than DexCom.
Volatility & Risk
DexCom has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Cytori Therapeutics has a beta of 2.78, meaning that its stock price is 178% more volatile than the S&P 500.
DexCom beats Cytori Therapeutics on 8 of the 13 factors compared between the two stocks.
DexCom Company Profile
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company’s markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.